SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply following reports of an upcoming partnership with Novo Nordisk to sell obesity drugs, signaling an end to their prior legal dispute. The unexpected collaboration has the community actively discussing the potential for a significant short squeeze, given the stock's high short interest, and anticipating substantial upside.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending as community discussion rages over President Trump's "Iran War" and new "Epstein files" allegations, fueling debate about rising gas prices and economic instability, with investors sharply divided on the company's outlook amidst global tensions.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending as community speculation mounts that the departure of a key FDA official may pave an easier regulatory path for its Huntington's disease gene therapy, fueling a significant rally and short squeeze chatter after prior data concerns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to significant community optimism following reports of Dr. Vinay Prasad's departure from the FDA, which many believe will foster a more permissive regulatory environment for gene therapies. This development, coupled with CEO Doug Ingram's announced retirement, is fueling M&A speculation and anticipation for upcoming DM1 and FSHD data.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network ($PI CRYPTO) is trending as its community actively discusses ongoing frustrations regarding coin migration, unverified balances, and the inability to trade on major exchanges, while a dedicated segment of users maintains a long-term bullish outlook despite these prolonged access challenges.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Anticipation of Rithm Capital's inclusion in the S&P SmallCap 600 is driving current interest, with the community highlighting expected "forced buying" from index funds. This is further fueled by discussions around the company's strong performance, recent strategic acquisitions, and the long-term potential of a C-Corp conversion to unlock its perceived undervaluation.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is highly volatile amid escalating Middle East tensions driving oil prices higher and intensifying inflation concerns, leading the community to debate potential market downturns and Federal Reserve policy implications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The bank now holds about 3.88 million shares, down from 17.8 million shares in September 2025.</li><li>Recently, the FDA issued warning letters to 30 telehealth companies over the misleading marketing of compounded GLP-1 weight-loss drugs.</li><li>Hims has faced scrutiny over its $49 compounded weight-loss pill, while Novo Nordisk filed a lawsuit against the company last month.</li></ul>Shares of Hims &amp; Hers Health, Inc. rose nearly 1% in early premarket trading on Friday, even as a new regulatory filing showed JPMorgan Chase &amp; Co. sharply reduced its stake.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> fell over 3% on Thursday to end at $15.88, but rose 0.4% in extended trading. Shares of the telehealth firm are on track to snap a 13-week losing streak.<h2 class="st-heading-2">JPMorgan Cuts Stake</h2>A new regulatory filing showed that JPMorgan held about 3.88 million shares, representing 1.7% of Hims &amp; Hers’ common stock as of Feb. 27, marking a sharp drop from 17.8 million, or about 8.1%, disclosed by the bank as of September 2025.The new filing indicates JPMorgan reduced its position by roughly 14 million shares, cutting its ownership to below the 5% disclosure threshold.<h2 class="st-heading-2">FDA Scrutiny Over Weight Loss Drugs</h2>The stake reduction comes as the digital health company faces growing regulatory scrutiny tied to its weight-loss offerings. The U.S. Food and Drug Administration (FDA) recently issued&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-overnight-fda-warns-telehealth-firms-glp1-claims/cZd99SIRI57">warning letters</a> to 30 telehealth companies over false or misleading marketing of compounded GLP-1 weight-loss drugs, including Semaglutide, Tirzepatide and Liraglutide, which are the active ingredients in Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro. Hims was also included in an earlier round of warning letters issued in September.The telehealth firm has also faced scrutiny over its $49 compounded weight-loss pill, while Novo Nordisk filed a lawsuit against the company last month. CEO Andrew Dudum said on the latest earnings call that GLP-1 users who use the compound form represent only a small minority of the platform’s subscribers as the company expands into other healthcare categories.<h2 class="st-heading-2">Peptides Emerge As Potential Growth Driver</h2>The scrutiny comes even as investors focus on&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-finds-glp1-hedge-rallies-rfk-jr-signals-peptide-clearances/cZdeIBHRI2w">peptides</a>, which are short chains of amino acids that regulate biological functions are being explored for uses such as muscle recovery and aging.&nbsp;Interest in the category has grown after&nbsp;U.S. Secretary of Health and Human Services&nbsp;Robert F. Kennedy Jr. said the FDA is reviewing whether some previously restricted peptides could again be produced by U.S. compounding pharmacies. The Futurum Group CEO Daniel Newman said that Hims “is the most likely public company play for peptides at scale” and said the category “could easily offset any GLP-1 related downside.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_04ed344d27.webp" alt="hims ss.png" width="969" height="144"><figcaption>HIMS sentiment and message volume as of March 6 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/TrendAnnihilator/message/646757398">expects</a> a “most likely choppy day tomorrow.”<stembedurl>https://stocktwits.com/TrendAnnihilator/message/646757398</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/AB5HUNNID/message/646749216">speculated</a>, “JP Morgan slashed 14 million shares Feb 27th on the day that short selling was restricted. THE STOCK RALLIED. Was JPM shorting all along?”<stembedurl>https://stocktwits.com/AB5HUNNID/message/646749216</stembedurl>HIMS stock has shed over half of its value so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown

The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.

Equity

Hims and Hers Expands Its Technology Driven Consumer Health Platform

HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.

William Blair Investment Management LLC Trims Stock Holdings in Hims & Hers Health, Inc. $HIMS

William Blair Investment Management LLC lowered its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 64.0% in the third quarter, according to the company in its most recent...

CI Investments Inc. Has $11.71 Million Position in Hims & Hers Health, Inc. $HIMS

CI Investments Inc. boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 6,659.7% during the third quarter, according to the company in its most recent filing with the...

<ul class="summary-bullets"><li>The FDA issued warning letters to 30 telehealth companies over allegedly misleading marketing tied to compounded GLP-1 weight-loss drugs.</li><li>Investor focus has also shifted to peptides, after Health Secretary Robert F. Kennedy Jr. said regulators are reviewing whether roughly 14 previously restricted peptides.</li><li>Retail traders largely dismissed the warning as a marketing issue, saying the dispute centers on advertising language, with some calling Hims a “deep value” stock.</li></ul>Shares of Hims &amp; Hers Health Inc. (HIMS) slipped more than 1% in overnight trading on Tuesday after the U.S. Food and Drug Administration (FDA) issued warning letters to 30 telehealth companies over false or misleading marketing claims tied to compounded GLP-1 weight-loss drugs.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> tumbled 4% to end at $15.82 on Tuesday and has shed over half of its value so far this year.<h2 class="st-heading-2">FDA Targets GLP-1 Marketing Claims</h2>The FDA said some companies promoted compounded medicines as equivalent to approved GLP-1 treatments or branded the products in ways that obscured&nbsp;their manufacturing location.The agency said the violations involved marketing claims around compounded Semaglutide, Sirzepatide and Liraglutide, the active ingredients used in Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Zepbound and Mounjaro.“It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action,” FDA Commissioner Marty Makary said in a statement.The companies have 15 working days to respond and outline corrective steps. The move follows an earlier round of warning letters sent in September to companies involved in selling weight-loss drugs, including Eli Lilly, Novo Nordisk and Hims, as part of a broader crackdown on drug advertising.Hims also came under fire recently after the FDA warned it could take action over the company’s $49 compounded weight-loss pill, while Novo Nordisk escalated the dispute last month by filing a lawsuit against the company.<h2 class="st-heading-2">Retail Traders Downplay Regulatory Risk</h2>On Stocktwits, retail sentiment for HIMS was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_ae53d337b0.webp" alt="hims ss.png" width="970" height="144"><figcaption>HIMS sentiment and message volume as of March 4 | Source: Stocktwits</figcaption></figure>Despite the warning letter, retail traders largely dismissed the move as a marketing issue rather than a fundamental threat to the company’s business model.Some users&nbsp;<a href="https://stocktwits.com/DadSuggests/message/646491751">noted</a> that regulators repeatedly focused on advertising and promotional claims, arguing the dispute centers on marketing language rather than the legality of compounded drugs. One trader&nbsp;<a href="https://stocktwits.com/DadSuggests/message/646511948">said</a> they were “not worried about FDA overhang.”Others&nbsp;<a href="https://stocktwits.com/BullRooster31/message/646507870">pointed</a> to the company’s potential growth in peptides and broader telehealth services, saying the firm&nbsp;<a href="https://stocktwits.com/GalacticFiskerShip/message/646491677">could</a> pivot toward brand-name GLP-1 drugs while expanding into new therapies and international markets. Users called Hims a “discount deep value stock.”<h2 class="st-heading-2">Peptides Seen As A Key Growth Driver</h2>Investor focus has increasingly shifted toward&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-finds-glp1-hedge-rallies-rfk-jr-signals-peptide-clearances/cZdeIBHRI2w">peptides</a> after the U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said regulators are reviewing whether several peptides that were previously restricted could be allowed for domestic compounding again.Peptides are small chains of amino acids that influence various biological processes. Some are promoted for benefits such as muscle growth, immune support and healthy aging, though effectiveness varies across different compounds.Kennedy said roughly 14 peptides could potentially move back to a category that allows U.S. compounding pharmacies to produce them. The Futurum Group CEO Daniel Newman said Hims &amp; Hers is “the most likely public company play for peptides at scale,” adding the category could offset potential GLP-1 related downside.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

<ul class="summary-bullets"><li>Robert F. Kennedy Jr. said the FDA is reviewing restrictions on peptides, with about 14 potentially returning to a category that allows U.S. compounding in the coming weeks.</li><li>Kennedy told The Joe Rogan Experience he hopes peptides will be accessible through “ethical suppliers.”</li><li>The company said on its latest earnings call that GLP-1 users represent only a small portion of subscribers.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) jumped on Monday after Robert F. Kennedy Jr. said the U.S. Food and Drug Administration (FDA) is reviewing the status of several peptides that were previously restricted, signaling a potential reopening of a fast-growing category that analysts say could benefit the digital health company.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped nearly 14% on Monday, posting its best session in over four months, to end at $16.48.&nbsp;<h2 class="st-heading-2">Peptide Reclassification Review Underway</h2>Speaking on The Joe Rogan Experience, Kennedy said that nearly two dozen peptides had previously been moved to a restricted category, preventing U.S.-based compounding pharmacies from legally producing them. He said the FDA is now considering moving roughly 14 of those peptides back to a category that would allow domestic compounding.“My hope is that they’re going to get moved to a place where people have access from ethical suppliers,” Kennedy said, while acknowledging that the scientific evidence supporting some uses of the peptides “hasn’t been fully gathered.”Kennedy argued that the earlier restriction contributed to a surge in gray-market sourcing. “We created the black market,” he said, describing how patients seeking peptides turned to unregulated suppliers once legal compounding options were removed.&nbsp;Peptides are short chains of amino acids that play a key role in regulating biological functions. Certain varieties are marketed for potential benefits, such as supporting muscle growth, enhancing immune response, and promoting healthier aging, though their effectiveness can vary by compound and clinical evidence.He said the original decision was framed around regulatory authority but maintained that safety concerns had not changed. According to Kennedy, the review underway could result in formal changes within the next few weeks. Kennedy added that he is personally supportive of peptide therapies, saying he is “a big fan of peptides” and has used them himself for injury recovery.The development comes as policymakers also examine broader therapeutic categories, including psychedelics and other non-traditional treatments, as part of a push to modernize access to certain therapies under tighter guidelines.<h2 class="st-heading-2">Peptide Shift A ‘Gamechanger’ For HIMS</h2>The Futurum Group CEO Daniel Newman&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/2028393809340469618">said on X</a> that Hims “is the most likely public company play for peptides at scale” and said the category “could easily offset any GLP-1 related downside.”Jonah Lupton, CEO and CIO of Lupton Capital, called the development a “gamechanger for the company and the stock price,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/JonahLupton/status/2028283530933911998">on X</a> and said that moving 14 peptides back to Category-1 would allow U.S.-based compounding pharmacies to produce and sell them without risk of shutdown.Lupton said the shift could bring “transparency, safety and accountability” to a market he expects to surpass $100 billion by 2030. He noted that Hims &amp; Hers acquired a U.S.-based peptide facility in California last year and now serves roughly 2.5 million members.“With 2.5 million members and growing (thanks to recent acquisitions),<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/search?q=%24HIMS&amp;src=cashtag_click"> $HIMS</a> is well positioned to capitalize on the peptide boom that I believe is about to take off around the world,” Lupton said.<h2 class="st-heading-2">CEO: GLP-1 A Small Share Of Subscribers</h2>The renewed focus on peptides comes as Hims &amp; Hers continues to navigate scrutiny around compounded GLP-1 offerings. On its most recent&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slumps-after-hours-how-ceo-dudum-plans-to-offset-glp-1-risk/cZRviIhR4z3">earnings call</a>, CEO Andrew Dudum said that GLP-1 users who are on a compounded regimen represent only a small minority of the company’s subscriber base. The company pointed to expansion across hormone therapy, lab diagnostics, dermatology, sexual health and menopause care as part of a broader preventive-health strategy.The company reiterated long-term financial targets of at least $6.5 billion in revenue and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2030, while noting that its 2026 outlook assumes continued access to compounded semaglutide.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for HIMS was ‘neutral’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_d444f7a0ca.webp" alt="hims ss.png" width="973" height="139"><figcaption>HIMS sentiment and message volume as of March 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RaihanMeazza/message/646391054">said</a>, “We're waiting for the market to cool off. Then, this will have a run!”<stembedurl>https://stocktwits.com/RaihanMeazza/message/646391054</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Pedje/message/646370934">said</a>, “peptides is the future. I lost 20 lbs on two months from taking Glp-3”<stembedurl>https://stocktwits.com/Pedje/message/646370934</stembedurl>HIMS stock has declined nearly 50% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances

The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale.

Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5% - Should You Buy?

Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5% - Here's Why...

Top Healthcare Stocks To Watch Now - March 2nd

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Novartis, Hims & Hers Health, and McKesson are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc...

Hims & Hers Expands Digital Health and Global Platform Strategy

HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.

Current Price	$15.74
Prev Close	$15.88
Open	$15.54
Dividend Yield	0.00%
50-Day Moving Average	$25.60
Beta	2.15
Avg. Volume	40.43M
PE Ratio	30.42

52-Week High	$70.43
52-Week Low	$13.74
Market Capitalization	$3.62B
EPS (Annual)	$0.5123
Price to Book	6.67
Revenue Per Employee	$961,358.31

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc